Hepatic cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hepatic cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Early Detection of Liver Cancer Using Hyperpolarized Pyruvate MRI for Patients with Primary Liver Cancer https://clinicaltrials.eu/trial/study-on-early-detection-of-liver-cancer-using-hyperpolarized-pyruvate-mri-for-patients-with-primary-liver-cancer/ Wed, 29 Apr 2026 15:05:15 +0000 https://clinicaltrials.eu/trial/study-on-early-detection-of-liver-cancer-using-hyperpolarized-pyruvate-mri-for-patients-with-primary-liver-cancer/ This clinical trial focuses on the early detection of primary liver cancer, also known as hepatocellular carcinoma. The study uses a special type of imaging called Hyperpolarized [1-13C]pyruvate MRI. This imaging technique involves injecting a contrast agent, which is a substance that helps make certain areas of the body more visible on the scan. The contrast agent used in this study is called Hyperpolarized [1-13C]pyruvate, which is a form of pyruvic acid. This trial aims to explore how well this imaging method can identify small tumors in the liver at an early stage.

Participants in the study will undergo the Hyperpolarized [1-13C]pyruvate MRI scan. This involves receiving an injection of the contrast agent through a vein, a process known as intravenous administration. The study will compare the results of these scans to standard imaging methods like MRI and CT scans, which are commonly used to diagnose liver cancer. The goal is to see if the new method can provide more detailed information about the metabolism and blood flow in liver tumors.

The study is designed to last until 2026, with participants being monitored over time to assess the effectiveness of the Hyperpolarized [1-13C]pyruvate MRI in detecting liver cancer early. This research could potentially lead to better ways of diagnosing liver cancer, especially in its early stages, which is crucial for effective treatment. The study does not involve any other diseases or medications, and participants may receive a placebo as part of the trial process.

]]>